Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 575

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 575
---
000 for the year ended December 31, 2023, which represent royalties and milestone payments earned in conjunction with ex-U.S. sales of KORSUVA/ Kapruvia under its agreements with CSL Vifor and Maruishi during the fourth quarter of 2023, which were sold to HCR under the HCR Agreement. There was no non-cash revenue recognized during the years ended December 31, 2022. Cost of Goods Sold

| ​                  
 ​                  | ​ 
 ​ | ​ 
 ​ | Year Ended December 31,     
 2023                        |   |       |   |   |   |          |   |       |   | ​ | ​ | 2022 |   |       |   |   |   |          |   |     |   | ​ 
 ​ |
|:-------------------|:--|:--|:----------------------------|:--|------:|:--|:--|:--|:---------|:--|:------|:--|:--|:--|:-----|:--|------:|:--|:--|:--|:---------|:--|:----|:--|:--|
| ​                  | ​ | ​ | Dollar amounts in thousands |   |       |   |   |   |          |   |       |   |   |   |      |   |       |   |   |   |          |   |     |   | ​ |
| ​                  | ​ | ​ | ​                           | ​ |     ​ | ​ | ​ | ​ | % change |   |       |   | ​ | ​ | ​    | ​ |     ​ | ​ | ​ | ​ | % change |   |     |   | ​ |
| Cost of Goods Sold | ​ | ​ | ​                           | $ | 6,174 | ​ | ​ | ​ | ​        | ​ | (15)% | ​ | ​ | ​ | ​    | $ | 7,266 | ​ | ​ | ​ | ​        | ​ | N/A | ​ | ​ |

During the years ended December 31, 2023 and 2022, Cara recorded COGS of $6.2 million and $7.3 million, respectively, which was related to its commercial supply revenue for KORSUVA injection sales to CSL Vifor. During the year ended December 31, 2023, COGS also included inventory write-downs of